Promising results for antiangiogenic compounds

[email protected] (Bill Brown) wrote in news:[email protected]:

> Hi,
>
> Some exciting news has just been published today about an antiangiogenic compound for cancer
> patients. Aeterna Laboratories, a Canadian Biotech, released its phase III clinical trial results
> on renal carcinoma. For a specific subgroup of patients, their product, the Neovastat, increased
> the median survival time by 109% for patients suffering of clear cell renal carcinoma with 1
> metastasis in the lung. These patients more than doubled their life expectancy from 12.6 months
> for the placebo group to 26.3% for the Neovastat group.
>
> This subpopulation represents some of the "healthier" patients in this study. It seems to confirm
> the paradigm that the earlier a patient is treated with anti-angiogenic compounds, the better his
> or her chances for a positive outcome.
>
> Angiogenesis control has been confirmed again to be a promising strategy to fight cancer. While
> waiting for more pharmaceutical results, there is one dietary supplement on the market with a
> similar mechanism of action, it's called CarTCell.
>
> Faithfully yours,
>
> Bill
>

Please explain how:
1. failure at top line analysis is "promising", and
2. results in a small, statistically insignificant sub-group (N=
3) are meaningful.

[email protected] (Bill Brown) wrote in message
news:<[email protected]>...
> Hi,
> > Angiogenesis control has been confirmed again to be a promising
> strategy to fight cancer. While waiting for more pharmaceutical results, there is one dietary
> supplement on the market with a similar mechanism of action, it's called CarTCell.
>
> Faithfully yours,
>
> Bill

Turmeric, the spice is about 40% curcumins, which are a very effective angiogenesis inhibitor.
Probably a lot cheaper than a boutique supplement.